You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY20 is not expected to be complete until September, 2021.

  1. Stable Glucagon for Treatment of Hyperinsulinism

    SBC: AMIDEBIO, LLC            Topic: 200

    In severe persistent hyperinsulinism (HI), repeated hypoglycemic episodes can ultimately lead to permanent seizure disorders, learning disabilities, cerebral palsy, blindness and even death. Clinical studies have demonstrated the effectiveness of both short-term and long-term treatment with glucagon for severe forms of HI and continuous subcutaneous administration of glucagon has been recommended ...

    SBIR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
  2. Development of Serious Games and Physical Activities Instructed by a Social Robot for Improving the Well-being of Elderly Individuals with Alzheimer's Disease and Dementia

    SBC: Dream Face Technologies, LLC            Topic: NIA

    The objective of the proposed direct Phase-II SBIR project is to develop and study and the effectiveness of Serious Games and physical Activities played/performed by elderly people with Alzheimer’s disease and AD- related Dementias in interaction with Ryan, our successfully piloted Socially Assistive Robot (SAR). Ryan is an intelligent conversational life-like social robot, designed to improve t ...

    SBIR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
  3. A Quality Control Program for Quantitative MRI DataAcquisition and Analysis in Multi-site Clinical Trials

    SBC: CaliberMRI, Inc.            Topic: 101

    Project Summary/Abstract There has been a shift to greater use of neadjuvant chemotherapy (NACT) in the clinical management of cancer. Often used in breast cancer to provide systemic treatment for possible or apparent metastatic disease, NACT also reduces the primary tumor size and facilitates breast conservation. Quantitative magnetic resonance imaging (qMRI) is an effective diagnostic for monito ...

    SBIR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
  4. Development of Ryan Companion Robot for Assisting Elderly People with Alzheimer's Disease

    SBC: Dream Face Technologies, LLC            Topic: NIA

    The objective of the proposed Fast-Track SBIR effort is to develop and commercialize the Ryan CompanionBot (hereafter, Ryan), an intelligent conversational life-like social robot, designed to improve the well-being and quality of life of older adults with early stage Alzheimerandapos;s disease (AD) and AD-Related Dementia (ADRD). According to the NIA, research reports estimate that as many as 5.1 ...

    SBIR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
  5. Lateral flow immunoassay for rapid diagnosis of tinea capitis and onychomycosis

    SBC: DxDiscovery Incorporated            Topic: NIBIB

    Tinea capitis (ringworm of the scalp) and onychomycosis (fungal nail infection) are infections that are most often caused by dermatophytes of the fungal genera Trichophyton and Microsporum. These two infections affect approximately 14 million people in the U.S. each year. Dermatophyte infections of the hair and nails are treated with oral antifungals for up to 12 weeks. Due to potential adverse ef ...

    SBIR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
  6. Rapid Test to Assist Therapy in Neonatal Sepsis and Necrotizing Enterocolitis

    SBC: PROTHERA BIOLOGICS, LLC            Topic: R

    The primary goal of this proposed research is to develop a rapid point-of-care test that assesses the risk of neonatal sepsis (NS) and/or necrotizing enterocolitis (NEC) in infants based on Inter-alpha inhibitor proteins (IAIP) levels in blood. The test is expected to be simple, user-friendly, portable and suitable for use in the NICU. NS and NEC are associated with high mortality and morbidity, i ...

    SBIR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
  7. Rapid, cost-effective whole genome screening tools for cryptic inversions and translocations

    SBC: KromaTiD, Inc.            Topic: 172

    ABSTRACT The proposed projectRapidcost effective whole genome screening tools for cryptic inversions and translocationswill advance a genomic approach to precision medicineenabling the discovery of diseasecausing genomic structural variations and reducing the risks associated with clinical gene editingStructural variations cause a wide range of diseases from rare diseases to cancersand can be prec ...

    SBIR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
  8. Developing, Testing and Validating a Wearable Alcohol Biosensor

    SBC: Clinitech, LLC            Topic: 450

    1 PROJECT SUMMARY2 This application for a Phase II SBIR award extends the successful completion of Phase I and represents a 3 collaboration between Clinitech, LLC and McLean Hospital/Harvard Medical School to continue the4 development of a wearable biosensor for detecting alcohol in the interstitial fluid of humans. Excessive use of5 alcohol accounts for much of the public health burden related to ...

    SBIR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
  9. In Vivo Studies of a Novel HDAC Inhibitor for Treating Hemoglobin Disorders

    SBC: Cetya Therapeutics, Inc.            Topic: NHLBI

    PROJECT SUMMARY The β-hemoglobinopathies are prevalent genetic blood diseases with few treatment options. It is estimate that 7% of the worldandapos;s population carries an abnormal hemoglobin gene with 400,000 infants born annually with a severe life threatening hemoglobinopathy. Drug mediated induction of normal, but developmentally silenced, fetal hemoglobin (HbF) expression reduces anemia and ...

    STTR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
  10. Point-of-Care Prognostic Tool for Sepsis

    SBC: Mbio Diagnostics, Inc.            Topic: 300

    Sepsis is a devastating cause of morbidity and mortality in intensive care units (ICUs), with estimates of U.S. incidence ranging from 894,000 to 3.1 million cases annually. The heterogeneity of clinical presentation (etiology, patient history, severity, etc.) creates a major challenge for patient management and has significantly complicated development of new therapies, almost all of which have f ...

    SBIR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government